Tamoxifen-induced apoptosis in breast cancer cells relates to down- regulation of bcl-2, but not bax and bcl-X(L), without alteration of p53 protein levels

Clinical Cancer Research

Volumn 5, Issue 10, 1999, Pages 2971-2977

  Zhang, Guo Jun ^a,b   Kimijima, Izo ^a   Onda, Masamitsu ^a   Kanno, Masahiko ^a   Sato, Hisayoshi ^a   Watanabe, Takanori ^a   Tsuchiya, Atsuo ^a   Abe, Rikiya ^b   Takenoshita, Seiichi ^a  

^a Ohara General Hospital   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2; PROTEIN P53; TAMOXIFEN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CONCENTRATION RESPONSE; DOWN REGULATION; DRUG EFFECT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS;

ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FEMALE; HUMANS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; TAMOXIFEN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032719052     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Tormey, D. C., Gray, R., and Falkson, H. C. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group [see comments]. J. Natl. Cancer Inst., 88: 1828-1833, 1996.
2. Rutqvist, L. E., Johansson, H., Signomklao, T., Johansson, U., Fornander, T., and Wilking, N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group [see comments]. J. Natl. Cancer Inst., 87: 645-651, 1995.
3. Nayfield, S. G. Tamoxifen's role in chemoprevention of breast cancer: an update. J. Cell Biochem. Suppl., 22: 42-50, 1995.
4. Frankfurt, O. S., Sugarbaker, E. V., Robb, J. A., and Villa, L. Synergistic induction of apoptosis in breast cancer cells by tamoxifen and calmodulin inhibitors. Cancer Lett., 97: 149-154, 1995.
5. Perry, R. R., Kang, Y., and Greaves, B. Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. Ann. Surg. Oncol., 2: 238-245, 1995.
6. Kang, Y., Cortina, R., and Perry, R. R. Role of c-myc in tamoxifen-induced apoptosis estrogen-independent breast cancer cells [see comments]. J. Natl. Cancer Inst., 88: 279-284, 1996.
7. Tsujimoto, Y., Finger, L. R., Yunis, J., Nowell, P. C., and Croce, C. M. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science (Washington DC), 226: 1097-1099, 1984.
8. Reed, J. C., Miyashita, T., Takayama, S., Wang, H. G., Sato, T., Krajewski, S., Aime-Sempe, C., Bodrug, S., Kitada, S., and Hanada, M. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J. Cell Biochem., 60: 23-32, 1996.
9. Reed, J. C. Bcl-2 and the regulation of programmed cell death. J. Cell Biol., 124: 1-6, 1994.
10. Gonzalez-Garcia, M., Perez-Ballestero, R., Ding, L., Duan, L., Boise, L. H., Thompson, C. B., and Nunez, G. bcl-XL is the major bcl-x mRNA form expressed during murine development and its product localizes to mitochondria. Development (Camb.), 120: 3033-3042, 1994.
11. Takayama, S., Sato, T., Krajewski, S., Kochel, K., Irie, S., Millan, J. A., and Reed, J. C. Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity. Cell, 80: 279-284, 1995.
12. Reynolds, J. E., Yang, T., Qian, L., Jenkinson, J. D., Zhou, P., Eastman, A., and Craig, R. W. Mcl-1, a member of the Bcl-2 family, delays apoptosis induced by c-Myc overexpression in Chinese hamster ovary cells. Cancer Res., 54: 6348-6352, 1994.
13. Krajewski, S., Blomqvist, C., Franssila, K., Krajewska, M., Wasenius, V. M., Niskanen, E., Nordling, S., and Reed, J. C. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res., 55: 4471-4478, 1995.
14. Yang, E., Zha, J., Jockel, J., Boise, L. H., Thompson, C. B., and Korsmeyer, S. J. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell, 80: 285-291, 1995.
15. Minn, A. J., Boise, L. H., and Thompson, C. B. Bcl-x(S) antagonizes the protective effects of Bcl-x(L). J. Biol Chem., 271: 6306-6312, 1996.
16. Reed, J. C., Miyashita, T., Takayama, S., Wang, H. G., Sato, T., Krajewski, S., Aime-Sempe, C., Bodrug, S., Kitada, S., and Hanada, M. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J. Cell Biochem., 60: 23-32, 1996.
17. Chresta, C. M., Masters, J. R., and Hickman, J. A. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res., 56: 1834-1841, 1996.
18. Huang, Y., Ray, S., Reed, J. C., Ibrado, A. M., Tang, C., Nawabi, A., and Bhalla, K. Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res. Treat., 42: 73-81, 1997.
19. Wang, T. T., and Phang, J. M. Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res., 55: 2487-2489, 1995.
20. L, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells. Clin. Cancer Res., 2: 1215-1219, 1996.
21. Miyashita, T., Krajewski, S., Krajewska, M., Wang, H. G., Lin, H. K., Liebermann, D. A., Hoffman, B., and Reed, J. C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 9: 1799-1805, 1994.
22. Germain, P., and Harbrioux, G. Modulation of the estradiol-17β mitogenic effect on human breast cancer MCF-7 cells by serum albumin in defined medium. Anticancer Res., 13: 1581-1585, 1993.
23. Haldar, S., Chintapalli, J., and Croce, C. M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res., 56: 1253-1255, 1996.
24. Miyashita, T., and Reed, J. C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood, 81: 151-157, 1993.
25. Jaattela, M., Benedict, M., Tewari, M., Shayman, J. A., and Dixit, V. M. Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. Oncogene, 10: 2297-2305, 1995.
26. Burow, M. E., Weldon, C. B., Tang, Y., Navar, G. L., Krajewski, S., Reed, J. C., Hammond, T. G., Clejan, S., and Beckman, B. S. Differences in susceptibility to tumor necrosis factor α-induced apoptosis among MCF-7 breast cancer cell variants. Cancer Res., 58: 4940-4946, 1998.
27. Chen, M., Quintans, J., Fuks, Z., Thompson, C., Kufe, D. W., and Weichselbaum, R. R. Suppression of Bcl-2 messenger RNA production may mediate apoptosis after ionizing radiation, tumor necrosis factor α, and ceramide. Cancer Res., 55: 991-994, 1995.
28. Wang, H. G., Rapp, U. R., and Reed, J. C. Bcl-2 targets the protein kinase Raf-1 to mitochondria [see comments]. Cell, 87: 629-638, 1996.
29. Blagosklonny, M. V., Schulte, T., Nguyen, P., Trepel, J., and Neckers, L. M. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res., 56: 1851-1854, 1996.
30. Zhang, G. J., Kimijima, I., Abe, R., Kanno, M., Katagata, N., Hara, K., Watanabe, T., and Tsuchiya, A. Correlation between the Expression of apoptosis-related bcl-2 and p53 oncoproteins and the carcinogenesis and progression of breast carcinomas. Clin. Cancer Res., 3: 2329-2336, 1997.
31. Teixeira, C., Reed, J. C., and Pratt, M. A. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res., 55: 3902-3907, 1995.
32. Seto, M., Jaeger, U., Hockett, R. D., Graninger, W., Bennett, S., Goldman, P., and Korsmeyer, S. J. Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J., 7: 123-131, 1988.
33. Dubik, D., and Shiu, R. P. C. Mechanism of estrogen activation of c-myc oncogene expression. Oncogene, 7: 1587-1594, 1992.
34. Haldar, S., Negrini, M., Monne, M., Sabbioni, S., and Croce, C. M. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res., 54: 2095-2097, 1994.
35. Sakamuro, D., Eviner, V., Elliott, K. J., Showe, L., White, E., and Prendergast, G. C. c-Myc induces apoptosis in epithelial cells by both p53-dependent and p53-independent mechanisms. Oncogene, 11: 2411-2418, 1995.
36. Caelles, C., Helmberg, A., and Karin, M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes [see comments]. Nature (Lond.), 370: 220-223, 1994.
37. Amellem, O., Stokke, T., Sandvik, J. A., Smedshammer, L., and Pettersen, E. O. Hypoxia-induced apoptosis in human cells with normal p53 status and function, without any alteration in the nuclear protein level. Exp. Cell Res., 232: 361-370, 1997.
38. Gee, J. M., Robertson, J. F., Ellis, I. O., Willsher, P., McClelland, R. A., Hoyle, H. B., Kyme, S. R., Finlay, P., Blamey, R. W., and Nicholson, R. I. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int. J. Cancer, 59: 619-628, 1994.
39. Silvestrini, R., Benini, E., Veneroni, S., Daidone, M. G., Tomasic, G., Squicciarini, P., and Salvadori, B. p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J. Clin. Oncol., 14: 1604-1610, 1996.
40. Zhang, G. J., Tsuda, H., Adachi, I., Fukutomi, T., Yamamoto, H., and Hirohashi, S. Prognostic indicators for breast cancer patients with one to three regional lymph node metastases, with special reference to alterations in expression levels of bcl-2, p53 and c-erbB-2 proteins. Jpn. J. Clin. Oncol., 27: 371-377, 1997.
41. Kitada, S., Takayama, S., De Riel, K., Tanaka, S., and Reed, J. C. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res. Dev., 4: 71-79, 1994.
42. Ziegler, A., Luedke, G. H., Fabbro, D., Altmann, K. H., Stahel, R. A., and Zangemeister-Writtke, U. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J. Natl. Cancer Inst., 89: 1027-1036, 1997.
43. Reed, J. C. Promise and problems of bcl-2 antisense therapy. J. Natl. Cancer Inst., 89: 988-990, 1997.